Clinical Trials

With over $1B in cash, Nektar is pushing its novel drug, rezpegaldesleukin, into final trials. It's a high-stakes bet on a new era for autoimmune care.

Inhibrx Biosciences lands a massive new loan to fuel its promising cancer drug trials, but rising costs and a wider net loss paint a high-stakes picture.

NervGen Pharma launches its pivotal Phase 3 RESTORE trial for spinal cord injury, backed by $61M in cash and new leadership, igniting hope for a new era of neuro-repair.

Biomea Fusion's new trial combines its drug icovamenib with semaglutide, aiming not just for weight loss, but to solve a major side effect: muscle loss.

After securing a $114M financing deal, Pyxis Oncology has extended its runway into 2027, putting all focus on upcoming MICVO data for head and neck cancer.

With promising data for its GX-03 cream in an underserved patient group, Turn Therapeutics expands its trial, hires an ex-FDA head, and eyes a new disease.

Atea's promising Hep C drug offers a shorter, simpler regimen for complex patients, but faces a tough market. Meanwhile, the firm tackles a neglected virus.

With pivotal data due in September, Connect Biopharma's rademikibart could redefine acute asthma and COPD care. Can it navigate this clinical tightrope?

With pivotal lung cancer data imminent, ArriVent BioPharma juggles a high-risk, high-reward strategy, betting its future on a novel drug and a new wave of ‘smart bomb’ therapies.

With an October FDA deadline for its lead drug, INOVIO walks a financial tightrope, betting its future on a first-in-class treatment and a broader DNA platform.

With a cash runway into 2029, Avalyn Pharma is advancing a novel inhaled drug platform, hitting key clinical milestones to challenge an oral-dominated market.

A new composition of matter patent extends protection for Alterity's lead drug to 2045, de-risking its path in MSA and opening a new front against Parkinson's.

A new partnership aims to bring the first FDA-approved, oral ketamine pill for depression to your home, using AI and real-world data to ensure safety.

With breakthrough dialysis data and a new heart-mending vessel, Humacyte is balancing radical innovation with commercial reality. Is this the future of medicine?

Early data for Sutro Biopharma's STRO-004 offers a glimmer of hope for advanced cancer patients. We look at the tech, the trials, and the financial tightrope.

As BioPorto preps its H1 2026 results, its promising NGAL kidney test faces a crucial moment. Can it sustain growth and appease a global market?

Aardvark Therapeutics faces a pivotal moment as an FDA clinical hold halts its lead drug trial, leaving the Prader-Willi Syndrome community waiting.

BridgeBio Oncology is doubling down on a costly strategy, betting that combining its novel drugs is the key to defeating hard-to-treat RAS-driven cancers.

With pivotal data imminent for two cancer drugs and a fortified balance sheet, SELLAS is at a crucial inflection point. Can it deliver on its promise?

Kodiak Sciences launches a pivotal trial for a new drug aiming to best current treatments for diabetic eye disease. Is this the future of vision care?